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Abstract
Background: The aim was to estimate the risk of subsequent extra-cervical Human Papillomavirus (HPV) related
cancer in patients surgically treated for high grade cervical intraepithelial neoplasia (CIN 2–3). This is the first study
in Italy investigating the occurrence of extra-cervical tumors in this cohort of patients.
Methods: 3184 patients surgically treated for CIN2–3 since 1992 at the Department of Surgical Sciences of
University of Torino were considered. The risk of HPV-related cancer was calculated as Standardized Incidence Ratio
(SIR), using as expected values tumour age specific incidence of resident population.
Results: 173 second primary cancer (SCPs) were identified. SIR to develop cancer after treatment for CIN2–3 was 2.2
(CI 95% 1.89–2.50). Among these occurrences, 10 are in HPV related sites: 1 anus (SIR = 1.8; 0.04–10.0), 3 vagina
(SIR = 12.4; 2.56–36.3), 1 vulva (SIR = 1.7; 0.04–9.59), 5 oropharynx (SIR = 8.5; 2.76–19.8).
Significant risk has been also recorded for pulmonary (SIR = 3.1; 0.70–5.27) and bladder (SIR = 4.05; 1.10–10.56), with
smoking as possible cofactor. We also found increased risk for breast (SIR = 2.4; 2.07–2.84) and ovarian cancers
(SIR = 2.1; 1.13–3.49), probably due to an higher adherence to spontaneous and programmed screening programs.
Conclusions: Our study supports the hypothesis of an increased risk of HPV-related tumours for CIN treated
patients, mostly for CIN3. It is conceivable the need of early diagnosis for these cancers in this higher-risk
populations.
Keywords: HPV-related cancers, Anogenital area, Anal cancer, Vaginal cancer, Vulvar cancer, Multiple subsequent
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Background
High-risk human papillomaviruses (hrHPV) are esti-
mated to cause 5.2% of all cancers worldwide, with
HPV16 alone responsible for approximately 70% of cer-
vical cancer, that is the first most common HPV-related
cancer in women [1]. HPV are also detectable in 15–
48% of vulvar, 68–86% of vaginal, 85–91% of anal,19–
25% of oropharyngeal, 3–5% of oral cavity, 2–5% of lar-
ynx cancers [2–5].
Precancerous lesions precede these cancers, and cervical
intraepithelial neoplasia (CIN) is the most studied and
treated. Despite CIN treatment has a high impact in redu-
cing cancer risk (from 95 to 99%), treated women are still
considered at higher risk of cervical malignancies com-
pared to the general population and at risk of HPV-
related malignancies in other body sites [6, 7]. Many stud-
ies demonstrated that women with history of diagnosis
and treatment for high-grade CIN are at increased risk for
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HPV subsequent primary cancers (SPCs) [6–16]. An
HPV-SPC is defined as a metachronous invasive primary
solid tumour, which develops at least 2months after the
diagnosis of a primary HPV-related tumour [17].
Viral, host, and behavioral variables may increase the
risk of cancer development allowing persistence of HPV
infection.
The viral genotype present influences risk and HPV 16
infection has the highest risk of viral persistence and
subsequent precancer/cancer development [15].
Host immunoresponse influence the effectiveness of
viral clearance: primary immunodeficiency disorders but
also polymorphisms in genes such as TLRs (Toll-Like re-
ceptors) and NF-kB networks are associated with higher
risk of lesions [18]. Also secondary immunodeficiencies
either infection-related (HIV) or iatrogenic (chemother-
apy or biological drugs) elevate the risk of HPV related
malignancies [4].
Sexual behaviors such as number of partners, young
age at first intercourse, frequency and type of sexual
practices and partners’ sexual histories are risk factors
for developing HPV related cancers [19]. Smoking is still
debate as risk factors, but it seems that it can play a role
in transition from HPV infection to precancer [20].
The aim of this study was to estimate the risk of devel-
oping SPCs and the site of occurrence in a cohort of
women resident in Piedmont (North-West Italy Region)
previously treated for high-grade CIN, distinguishing be-
tween HPV-related and non-HPV-related sites.
This is, at our knowledge, the first study in Italian
population with the aim to provide accurate risk esti-
mates of occurrence of a prior CIN represents an in-
creased risk for HPV-related SPCs.
Methods
Individual clinical information on all patients surgically
treated with large loop excision of transformation zone
(LLETZ) procedure at the Department of Surgical Sciences
of the University of Torino, St. Anna Hospital for high-
grade CIN from 1992 to 2016 were recruited in the cohort
(6649 patients). Women treated after 2014 were excluded
in order to have at least 5 years of follow-up for each pa-
tient, reducing the cohort at 5595 women. This database
was linked with the Piedmont Cancer Registry (Registro
Tumori Piemonte: RTP) to retrieve information on subse-
quent neoplasm (excluding non-melanoma skin cancers).
RTP registered cancers among residents only in the Muni-
cipality of Turin between 1985 and 2007, the residents in
the larger Turin Metropolitan Area since 2008, and finally
in the whole region since 2013. Patients in the cohort were
considered only if resident in the corresponding area for
the period above mentioned, otherwise they were discarded
from the cohort. The study cohort was thus reduced to
3184 patients.
Expected cases by type of cancer were calculated in the
reduced cohort applying corresponding specific rates
[http://ci5.iarc.fr; www.cpo.it] by age class (five-year groups:
0–85+), period (Turin Municipality: years 1992–1997,
1998–2002, 2003–2007, 2008–2012, 2013–2014; Metropol-
itan Area: years 2008–2012, 2013–2014; Piedmont Region:
years 2013–2014) and cancer site. Person-years in the co-
hort were calculated with month approximation at follow-
up date and time of surgery (as starting observation time).
All tumours were classified by anatomical site using
the International Classification of Cancer Pathologies,
3rd edition ICD-O 3. Risk of SPCs was then calculated
dividing number of observed and expected cases as Stan-
dardized Incidence Ratio (SIR). Confidence interval of
SIR were derived using Haenszel’s exact method [21].
Results
The study cohort of 3184 patients resident in Piedmont
during the period and in the area of RTP registration
was observed for a total of 20,022 person-years up to the
end of 2014.
In this period, a total of 173 neoplasms were registered
in these women (Table 1) with an overall SIR of 2.2
(95% exact CI: 1.89–2.50). In particular, HPV-related
cancer site showed an important and statistically signifi-
cant risk increase in patients surgically treated for
CIN2–3. Overall oropharynx cancers (5 cases) exhibited
a SIR of 8.5 (95% exact CI: 2.76–19.8). Tongue cancers
were the most frequent among them, 4 occurrences and
SIR of 14.1 (95% exact CI: 3.84–36.2).
We had a SIR of 1.8 (95% exact CI: 0.04–10.00) in anal
area, 1,7 (95% exact CI: 0.04–9.59) and 12.4 (95% exact CI:
2.56–36.3) in vulvar and vaginal localization respectively.
Summing up all these HPV related sites we had 10
cases with a significant SIR of 5.1 (95% exact CI: 2.44–
9.38). For each positive case of SPC, we checked, con-
sulting the database created, whether patients were
treated for CIN 2 or CIN 3: an higher risk of developing
SPCs was found in CIN 3 treated patients, SIR of 6.08
(95% exact CI: 2.44–12.53), compared to CIN2, SIR of
1.43 (95% exact CI: 0.57–2.94). (Table 2).
An excess risk of other cancers not strictly related to HPV
infection was also observed. In particular, 15 lung cancers,
SIR 3.1 (95% exact CI: 0.70–5.27); 3 bladder cancers, SIR
4.05 (95% exact CI: 1.10–10.56). 62 subsequent breast can-
cers and 7 ovarian cancers ((SIR respectively 2.4 (95% exact
CI: 2.07–2.84) and 2.1 (95% exact CI: 1.13–3.49)).
Discussion
The study was performed to estimate the risk of SPCs in
extra-cervical sites in women surgically treated for CIN 2
and CIN 3. Recently, similar studies have been published,
with slightly different criteria of inclusion [6–14, 16, 22–
24]. Sexually transmitted HPV infection is common, but
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usually transient: 80% of infected women spontaneously
eliminate HPV within 2 years of acquisition [3].
The presence of high-grade CIN is a good proxy for
persistent high-risk HPV infection. The common viral
HPV aetiology for a subset of extra cervical tumours fac-
tor explains why women with history of CIN2 or CIN3
have a significantly higher risk of anal, vulvar, vaginal,
and oral cancer [16, 25].
Women whose inadequate immune response failed to
clear HPV infection and allowed viral persistence and
CIN development are at higher risk for HPV persistence
after CIN treatment and subsequent related lesions [24].
An immunological failure could be present, together
with other specific risks, in other body sites, conse-
quently increasing the risk of lesions elsewhere [4, 17].
The common risk factors as HPV 16 persistent infection
and other behavioural factors as smoking and sexual
practices could also increase risk for SPCs development,
in the presence of a persistent HPV infection [3].
Anogenital region
In (Table 3) we compare our study with the literature
data. All studies use SIR or Relative Risk (RR) to esti-
mate the correlation between primary cervical lesions
and SPCs.
Table 1 Observed subsequent cancers in a cohort of patients
treated with LLETZ for CIN2–3 [excluding non-melanoma skin
cancers]



























ICDO-3 International Classification of Diseases for Oncology 3rd Edition
LLETZ Large Loop Excision of the Transformation Zone
SPCs Second Primary Cancers
Table 2 HPV-related cancers in CIN 2–3 LLETZ treated patients.








Oropharynx C01-C10 5 0.59 8.5 2.76–19.8
Anus C21 1 0.55 1.8 0.04–10.0
Vulva C51 1 0.58 1.7 0.04–9.59
Vagina C52 3 0.24 12.4 2.56–36.3
Total 10 1.96 5.1 2.44–9.38
Legenda:
ICDO-3 International Classification of Diseases for Oncology 3rd Edition
LLETZ Large Loop Excision of the Transformation Zone
SPCs Second Primary Cancers
SIR Standardized Incidence Ratio
CI Confidence Interval
Table 3 Anogenital SPCs in CIN 2–3 LLETZ treated women. A
comparison between literature and our study data
Author Year First lesion Value Vulva Vagina Anus
Evans [26] 2003 CIN 3 SIR 4.4 18.5 5.9
Kalliala [6] 2005 CIN 1–3 SIR 4.1 12 5.7
Edgren [9] 2007 CIN 3 IRR 2.2 6.7 4.7
Strander [22] 2007 CIN 3 RR 6.8
Saleem [12] 2007 CIN3 SIR – – 16.4
SCC SIR – – 6.2
Tatti [27] 2012 CIN 2–3 OR – – 1.91
Gaudet [10] 2014 CIN 2 SIR 1.47 3.61 0.89
CIN 3 SIR 3.79 8.53 2.28
CIN2–3 SIR 2.9 6.65 1.75
Sand [11] 2016 CIN 2 RR 2.5 8.1 2.9
CIN 3 RR 4 17.1 4.2
Ebisch [8] 2017 CIN 3 IRR 4.97 86.08 3.85
Suk [23] 2018 SCC SIR 3.8 17.3 2.3
Acevedo
Fontánez [14]
2018 SCC SIR – – 51.6
Wang [16] 2020 SCC SIR 2.29 1.85 1.41
Our study CIN 2–3 SIR 1.7 12.4 1.8
Legenda:
CIN Cervical Intraepithelial Neoplasia
IRR Incidence Rate Ratio
LLETZ Large Loop Excision of the Transformation Zone
RR Relative Risk
SCC Invasive Squamous Cell Carcinoma
Preti et al. BMC Cancer          (2020) 20:972 Page 3 of 7
Surgical removal (LLETZ) of CIN does not mean re-
moval of HPV infection and HPV DNA can be present in
surrounding, clinical normal tissues and this viral persist-
ence can rise the subsequent precancer/cancer risk [7].
The correlation between anogenital tumour or pre-
tumour lesions and HPV infection has been well de-
scribed [18]. There is general consensus in stating that
patients treated for high grade CIN or cervical cancer
are at increased risk of invasive neoplasia and our study
confirms this trend [5–14, 16].
In our study all SPCs found in anal, vulvar and vaginal
sites occurred in women with previous history of CIN 3.
No case of CIN 2 determined SPCs in the anogenital
area. This could be explained by the more reproducible
diagnosis of CIN 3 respect to CIN 2 and with the longer
HPV persistence to achieve CIN3/carcinoma in situ le-
sions [28]. Also HPV-induced field effect is a risk factor
for multicentric disease, as a persistent lesion allows
continuous spreading of infective HPV [29].
Head-neck
The role of HPV in the pathogenesis of a subset of head
and neck tumours, in particular in oropharyngeal squa-
mous cell tumours (OPSCCs), has been well established
[30, 31]. Patients with HPV-related cancers are more fre-
quently younger and with a better prognosis than those
with OPSCCs HPV-negative [31]. Numerous studies in
the literature show an increased risk of SPCs onset after
anogenital HPV-related lesion [6–8, 10, 23, 26]. We con-
firmed this evidence. (Table 4) compares the values of
the literature with our study.
A Danish study shows that women with HPV-related
OPSCC are more likely to be affected by cervical disease:
the association between oral and cervical HPV related
lesions is stronger for smoking patients than for non-
smokers [30]. Also sexual behaviours as unprotected oral
sex and number of lifetime partners are considered risk
factors. With the exception of HPV16, the HPV types
that infect the cervix are different from those of oral
area, and carcinogenesis mechanisms are not identical,
even not yet fully understood [31]. OPSCC arise in a dif-
ferent epithelium from the cervical one without trans-
formation zone, and no preinvasive oral lesion can be
identified up to date. HPV genome integration occurs
with different patterns: in cervical cancer through the
classic E2 breakpoint, while in OPSCC throughout the
entire genome, more frequently in E1 [31].
Unfortunately, we could not perform stratification to
smoking habit because this information was not system-
atically recorded in our database.
Lung and bladder
There is recent hypothesis about the role of HPV in
these cancers [32]. The most plausible cause of correl-
ation between cervical and lung or bladder cancers is the
common risk factor of smoking [32–34].
It has been hypothesized an association between blad-
der cancer and HPV. Anatomical proximity could be a
potential cause for viral migration, since in women ur-
ethra is close to anogenital area which could be a reser-
voir for HPV. Also natural HPV tropism for squamous
epithelium could facilitate infection [35].
As for lung, there is a variable reported incidence of
HPV DNA in lung cancer specimens and it has been
speculated that HPV reaches the lungs via the blood-
stream, even if it is known that HPV does not cause gen-
eralized viremia [36]. It has been also proposed that
HPV particles may be carried though air, raising the po-
tential issue of occupational exposure for healthcare pro-
viders and exposure for patients during LLETZ
procedures [37].
In our series all SPCs occurred after a CIN3 history,
whereas in the lungs a greater heterogeneity of results was
found: 9.8% after CIN1 history, 35.7% after CIN2 and
35.7% after CIN3. While 25% of bladder lesions occur
after CIN2 history and 75% after treatment for CIN 3.
Other Gynaecological sites
Some studies aimed to find a biologically and clinically
plausible explanation for breast or ovarian tumour oc-
currences in patients with a history of HPV-related le-
sions. Despite these studies, the scientific evidences of
HPV involvement in breast carcinogenesis is not suffi-
cient yet [38, 39]. In breast and ovary numerous tumour
occurrences have been found. We thought that this in-
creased risk could depend on increased diagnostic atten-
tion and adherence to organized and spontaneous
screening programs.
Table 4 Head and neck SPCs in CIN 2–3 LLETZ treated women.
A comparison between literature and our study data
Author Year First lesion Value Head and Neck
Evans [26] 2003 CIN 3 SIR 1.2
Kalliala [6] 2005 CIN 1–3 SIR 1.7
Gaudet [10] 2014 CIN 2 SIR 0.47
CIN 3 SIR 0.67
Ebisch [8] 2017 CIN 3 IRR 5.51
Suk [23] 2018 SCC SIR 1.4
Wang [16] 2020 SCC SIR 2.29
Our study CIN 2–3 SIR 8.5
Legenda:
CIN Cervical Intraepithelial Neoplasia
IRR Incidence Rate Ratio
LLETZ Large Loop Excision of the Transformation Zone
SCC Invasive Squamous Cell Carcinoma
SIR Standardized Incidence Ratio
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The role of hormones in tumorigenesis in breast, ovary
and thyroid cancers is to be considered as a possible
common risk factor.
Conclusions
Cervical cancer screening program in Italy is constantly
updated by GISCI, Italian Cervicocarcinoma Screening
Group (www.gisci.it). Due to the low incidence of anal
cancer (1–3 cases/100,000 women-years), vaginal cancer
(0.5–1.7 cases/100,000 women-years) and vulvar cancer
(1-to 4.6 cases/100,000 women-years) there are no cost-
effective screening programs for these tumours [40–43].
As invasive tumour lesions in these sites are preceded
by pre-tumoral lesions and non-invasive diagnostic ex-
aminations are available, it could be appropriate to con-
sider women treated for CIN3, as at greater risk of other
HPV-related cancers, to be target of screening strategies.
To plan appropriate program for cervical precancer
and cancer detection it should be suggested to continue
screening after the age that usually negative women stop
(65 years in Italy), as risk continues to be elevated even
after 20 years from first treatment [7].
This prolongation or even a lifelong cervical cancer
screening will allow detection of vaginal, vulvar and anal
precancerous lesions too. For vaginal cancer, the person-
alized follow-up program would benefit from the high
sensitivity of validated HPV tests combined with the
high specificity of the cytology and colposcopy. Vulvar
preinvasive lesions could also be detected during routine
examination before the insertion of vaginal speculum to
perform HPV or PAP test, through the correct and con-
scious inspection of the external genitalia. Thus it is of
paramount importance to train healthcare providers
(general practitioners, gynecologists and midwives) to a
general assessment of genitalia.
In anal region, screening in CIN3 treated patients
could use a threefold approach: cytology, high-resolution
anoscopy and guided biopsy as the best resource cur-
rently available [44]. However there are no validated ap-
proaches to anal cancer screening due to its low
incidence and the best option is limiting screening to
highest risk subgroup, such as immunodepressed women
(either from HIV or iatrogenic immunosuppression),
women with multiple sexual partners, heavy smokers
and with history of anal warts [45].
Despite the high specificity (92%) and moderate sensitiv-
ity (72%) of oral HPV detection methods [oral rinsing and
oral swabs], even for head and neck cancers the opportun-
ity of a screening program is affected by the low incidence
in the general population of the same, especially in
women. Moreover, unlike tumours in the anogenital area,
there is no pre-tumour lesion that anticipates oral and
oropharyngeal cancers, this further compromises the use-
fulness of a screening strategy [30, 46].
It remains to assess the impact of adjuvant HPV vac-
cination in treated patients: it has already demonstrated
a protective effect in reducing recurrent intraepithelial
cervical lesion but further studies are needed to evaluate
the impact on HPV-related SPCs [47].
There are some limitations in our study. First the type
of treatment of cervical lesions, LLETZ, could have in-
fluenced the study outcome, since it removes less tissue
than cold knife conization. If this approach is of utmost
clinical benefit for reduction of adverse obstetrics out-
comes, it can leave in situ more HPV infected tissue.
Also positive margin status and glandular involvement
from a less invasive treatment could have influenced, as
a result of incomplete excision or a lesion hidden in the
glandular crypts. Secondly, our database is not represen-
tative of the entire Italian population but based on a re-
gional cancer registry. Furthermore, we assumed that
SPCs can be attributable to HPV infection persistence
but HPV testing was not available in our retrospective
database.
The increased risk of cancer in extra-cervical sites after
CIN 2–3 treatment makes appropriate to introduce per-
sonalized follow-up and screening programs, while HPV
vaccination needs further studies to assess its impact. The
best strategy should be defined according to the economic
budget of public health and to the workload of the hos-
pital units in charge of their implementation.
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